Glucophage Xr

Glucophage XR is an extended‑release tablet that contains the active ingredient Metformin Hydrochloride; the specific strength is not listed. It belongs to the biguanide class of oral antidiabetic agents and is marketed in the European Union as a prescription‑only medication for managing blood glucose levels. It is taken orally and works by decreasing hepatic glucose production while improving peripheral insulin sensitivity. The formulation releases the drug gradually over several hours.

Glucophage XR is indicated for the long‑term management of type 2 diabetes mellitus in adults.

- As monotherapy in patients whose diet and exercise do not achieve glycemic control. - In combination with other oral antidiabetic agents such as sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. - As part of a comprehensive treatment plan that includes lifestyle modification. - For patients with renal function within recommended limits to reduce risk of lactic acidosis. - To improve insulin sensitivity in peripheral tissues.

The safety profile of Glucophage XR includes a range of adverse events that are categorized by frequency and severity.

Common: - Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Decreased appetite or weight loss. - Mild headache.

Serious: - Lactic acidosis, a rare but potentially fatal metabolic complication. - Severe hypoglycemia when used with insulin or insulin secretagogues. - Hepatotoxicity presenting as elevated liver enzymes. - Skin reactions such as rash or Stevens‑Johnson syndrome.

Before prescribing Glucophage XR, clinicians should evaluate several patient‑specific factors to minimize risks.

- Assess renal function; avoid use in patients with eGFR below the recommended threshold. - Review hepatic status, as liver disease can increase the risk of lactic acidosis. - Consider pregnancy and lactation status; the drug is category B but should be used only if benefits outweigh risks. - Monitor vitamin B12 levels during long‑term therapy, as deficiency may develop. - Advise patients to avoid excessive alcohol consumption, which can potentiate lactic acidosis. - Ensure proper dosing schedule to maintain extended‑release formulation integrity.

Glucophage XR may interact with other medicines, altering its effectiveness or increasing adverse effects.

Avoid: - Concomitant use with iodinated contrast agents for imaging studies without appropriate renal monitoring. - Co‑administration with potent CYP450 inhibitors that significantly raise metformin plasma levels (e.g., cimetidine). - Use with other agents known to cause lactic acidosis, such as certain antiretrovirals.

Use with caution: - Combination with insulin or insulin secretagogues, which can increase hypoglycemia risk. - Concurrent use of diuretics that may affect renal function and metformin clearance. - Co‑administration with drugs that affect vitamin B12 absorption, such as proton pump inhibitors. - Use with other oral antidiabetics, requiring dose adjustments and close glucose monitoring.